Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines

Cancer Medicine

Volumn 4, Issue 3, 2015, Pages 392-403

  Goecks, Jeremy ^a   El Rayes, Bassel F ^b   Maithel, Shishir K ^b   Khoury, H Jean ^b   Taylor, James ^c   Rossi, Michael R ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Analysis pipelines; Bioinformatics; Galaxy; Genomic tumor profiles; Pancreatic cancer

Indexed keywords

TRANSCRIPTOME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; EXOME; GENE EXPRESSION; GENE FREQUENCY; GENE FUSION; HUMAN; INDEL MUTATION; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; TUMOR SUPPRESSOR GENE; CELL LINE; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; MUTATION; PANCREAS TUMOR; SEQUENCE ANALYSIS; TUMOR CELL LINE;

CELL LINE; CELL LINE, TUMOR; EXOME; GENE EXPRESSION PROFILING; GENES, NEOPLASM; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, ERBB-2; SEQUENCE ANALYSIS, RNA;

EID: 84979866821     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.360     Document Type: Article

References (52)

1. Paez, J. G., P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
2. Chapman, P. B., A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-2516.
3. Paik, S., S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, et al. 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351:2817-2826.
4. Chang, J. C., E. C. Wooten, A. Tsimelzon, S. G. Hilsenbeck, M. C. Gutierrez, R. Elledge, et al. 2003. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369.
5. Soda, M., Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, et al. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566.
6. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-792.
7. Weinstein, J. N., E. A. Collisson, G. B. Mills, K. R. Shaw, B. A. Ozenberger, K. Ellrott, et al. 2013. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45:1113-1120.
8. Stratton, M. R. 2011. Exploring the genomes of cancer cells: progress and promise. Science 331:1553-1558.
9. Roychowdhury, S., M. K. Iyer, D. R. Robinson, R. J. Lonigro, Y. M. Wu, X. Cao, et al. 2011. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3:111ra121.
10. Weinstein, I. B., and A. Joe . 2008. Oncogene addiction. Cancer Res. 68:3077-3080; discussion 3080.
11. Torti, D., and L. Trusolino . 2011. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med. 3:623-636.
12. Luo, J., N. L. Solimini, and S. J. Elledge . 2009. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823-837.
13. Forbes, S. A., N. Bindal, S. Bamford, C. Cole, C. Y. Kok, D. Beare, et al. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39:D945-D950.
14. Griffith, M., O. L. Griffith, A. C. Coffman, J. V. Weible, J. F. McMichael, N. C. Spies, et al. 2013. DGIdb: mining the druggable genome. Nat. Methods 10:1209-1210.
15. Barretina, J., G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607.
16. Jang, S., and M. B. Atkins . 2014. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin. Pharmacol. Ther. 95:24-31.
17. Jang, S., and M. B. Atkins . 2013. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 14:e60-e69.
18. Dudley, J. T., R. Chen, and A. J. Butte . 2011. Matching cancer genomes to established cell lines for personalized oncology. Pac. Symp. Biocomput.. 243-252.
19. Collins, F. S., and L. A. Tabak . 2014. Policy: NIH plans to enhance reproducibility. Nature 505:612-613.
20. Reich, M., T. Liefeld, J. Gould, J. Lerner, P. Tamayo, and J. P. Mesirov . 2006. GenePattern 2.0. Nat. Genet. 38:500-501.
21. Oinn, T., M. Addis, J. Ferris, D. Marvin, M. Senger, M. Greenwood, et al. 2004. Taverna: a tool for the composition and enactment of bioinformatics workflows. Bioinformatics 20:3045-3054.
22. Omberg, L., K. Ellrott, Y. Yuan, C. Kandoth, C. Wong, M. R. Kellen, et al. 2013. Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat. Genet. 45:1121-1126.
23. Goecks, J., A. Nekrutenko, J. Taylor, and T. Galaxy . 2010. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 11:R86.
24. Blankenberg, D., J. Taylor, A. Nekrutenko, and T. Galaxy . 2011. Making whole genome multiple alignments usable for biologists. Bioinformatics 27:2426-2428.
25. Blankenberg, D., N. Coraor, G. Von Kuster, J. Taylor, A. Nekrutenko, and T. Galaxy . 2011. Integrating diverse databases into an unified analysis framework: a Galaxy approach. Database (Oxford) 2011:bar011.
26. Afgan, E., D. Baker, N. Coraor, H. Goto, I. M. Paul, K. D. Makova, et al. 2011. Harnessing cloud computing with Galaxy Cloud. Nat. Biotechnol. 29:972-974.
27. Li, H., and R. Durbin . 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754-1760.
28. Koboldt, D. C., Q. Zhang, D. E. Larson, D. Shen, M. D. McLellan, L. Lin, et al. 2012. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22:568-576.
29. Kim, D., G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, and S. L. Salzberg . 2013. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14:R36.
30. Quinn, E. M., P. Cormican, E. M. Kenny, M. Hill, R. Anney, M. Gill, et al. 2013. Development of strategies for SNP detection in RNA-seq data: application to lymphoblastoid cell lines and evaluation using 1000 Genomes data. PLoS One 8:e58815.
31. Trapnell, C., A. Roberts, L. Goff, G. Pertea, D. Kim, D. R. Kelley, et al. 2012. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7:562-578.
32. Kim, D., and S. L. Salzberg . 2011. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 12:R72.
33. Wang, K., M. Li, and H. Hakonarson . 2010. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38:e164.
34. Genomes Project C; G. R. Abecasis, D. Altshuler, A. Auton, L. D. Brooks, R. M. Durbin, R. A. Gibbs, M. E. Hurles, and G. A. McVean . 2010. A map of human genome variation from population-scale sequencing. Nature 467:1061-1073.
35. Tennessen, J. A., A. W. Bigham, T. D. O'Connor, W. Fu, E. E. Kenny, S. Gravel, et al. 2012. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337:64-69.
36. Sloggett, C., N. Goonasekera, and E. Afgan . 2013. BioBlend: automating pipeline analyses within Galaxy and CloudMan. Bioinformatics 29:1685-1686.
37. Goecks, J., C. Eberhard, T. Too, T. Galaxy, A. Nekrutenko, and J. Taylor . 2013. Web-based visual analysis for high-throughput genomics. BMC Genom. 14:397.
38. Goecks, J., N. Coraor, T. Galaxy, A. Nekrutenko, and J. Taylor . 2012. NGS analyses by visualization with Trackster. Nat. Biotechnol. 30:1036-1039.
39. Krzywinski, M., J. Schein, I. Birol, J. Connors, R. Gascoyne, D. Horsman, et al. 2009. Circos: an information aesthetic for comparative genomics. Genome Res. 19:1639-1645.
40. Cox, A. D., and C. J. Der . 2010. Ras history: the saga continues. Small GTPases 1:2-27.
41. Schubbert, S., K. Shannon, and G. Bollag . 2007. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7:295-308.
42. Baker, N. M., and C. J. Der . 2013. Cancer: drug for an 'undruggable' protein. Nature 497:577-578.
43. Tse, M. T. 2013. Anticancer drugs: a new approach for blocking KRAS. Nat. Rev. Drug Discov. 12:506.
44. Zimmermann, G., B. Papke, S. Ismail, N. Vartak, A. Chandra, M. Hoffmann, et al. 2013. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497:638-642.
45. Mackenzie, G. G., L. E. Bartels, G. Xie, I. Papayannis, N. Alston, K. Vrankova, et al. 2013. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice. Neoplasia 15:1184-1195.
46. Kim, S. T., H. Lim do, K. T. Jang, T. Lim, J. Lee, Y. L. Choi, et al. 2011. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol. Cancer Ther. 10:1993-1999.
47. McDonald, S. A., E. R. Mardis, D. Ota, M. A. Watson, J. D. Pfeifer, and J. M. Green . 2012. Comprehensive genomic studies: emerging regulatory, strategic, and quality assurance challenges for biorepositories. Am. J. Clin. Pathol. 138:31-41.
48. Liang, W. S., D. W. Craig, J. Carpten, M. J. Borad, M. J. Demeure, G. J. Weiss, et al. 2012. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One 7:e43192.
49. Shimada, H., M. Kuboshima, T. Shiratori, Y. Nabeya, A. Takeuchi, H. Takagi, et al. 2007. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int. J. Oncol. 30:97-103.
50. O'Donnell, P. H., A. L. Stark, E. R. Gamazon, H. E. Wheeler, B. E. McIlwee, L. Gorsic, et al. 2012. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer 118:4063-4073.
51. Kelber, J. A., T. Reno, S. Kaushal, C. Metildi, T. Wright, K. Stoletov, et al. 2012. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res. 72:2554-2564.
52. Montemurro, F., and M. Scaltriti . 2014. Biomarkers of drugs targeting HER-family signalling in cancer. J. Pathol. 232:219-229.